JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : BMB Reports
  • Volume 49, Issue 5,  2016, pp.270-275
  • Publisher : Korean Society for Biochemistry and Molecular Biology
  • DOI : 10.5483/BMBRep.2016.49.5.187
 Title & Authors
Proteasome inhibitors attenuated cholesterol-induced cardiac hypertrophy in H9c2 cells
Lee, Hyunjung; Park, Jinyoung; Kim, Eunice EunKyeong; Yoo, Young Sook; Song, Eun Joo;
  PDF(new window)
 Abstract
The Ubiquitin proteasome system (UPS) plays roles in protein degradation, cell cycle control, and growth and inflammatory cell signaling. Dysfunction of UPS in cardiac diseases has been seen in many studies. Cholesterol acts as an inducer of cardiac hypertrophy. In this study, the effect of proteasome inhibitors on the cholesterol-induced hypertrophic growth in H9c2 cells is examined in order to observe whether UPS is involved in cardiac hypertrophy. The treatment of proteasome inhibitors MG132 and Bortezomib markedly reduced cellular surface area and mRNA expression of β-MHC in cholesterol-induced cardiac hypertrophy. In addition, activated AKT and ERK were significantly attenuated by MG132 and Bortezomib in cholesterol-induced cardiac hypertrophy. We demonstrated that cholesterol-induced cardiac hypertrophy was suppressed by proteasome inhibitors. Thus, regulatory mechanism of cholesterol-induced cardiac hypertrophy by proteasome inhibitors may provide a new therapeutic strategy to prevent the progression of heart failure.
 Keywords
Brotezomib;Cholesterol-induced cardiac hypertrophy;H9c2 cells;MG132;Proteasome inhibitors;
 Language
English
 Cited by
 References
1.
Frey N, Katus HA, Olson EN and Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109, 1580-1589 crossref(new window)

2.
Glenn DJ, Rahmutula D, Nishimoto M et al (2009) Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism. Cardiovasc Res 84, 209-217 crossref(new window)

3.
Eom GH, Kook H (2015) Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy. BMB Rep 48, 131-138 crossref(new window)

4.
Glickman MH and Ciechanover A (2002) The ubiquitinproteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373-428 crossref(new window)

5.
Hershko A and Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425-479 crossref(new window)

6.
Voges D, Zwickl P and Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68, 1015-1068 crossref(new window)

7.
Birks EJ, Latif N, Enesa K (2008) Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res 79, 472-480 crossref(new window)

8.
Powell SR, Wang P, Katzeff H et al (2005) Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome. Antioxid Redox Signal 7, 538-546 crossref(new window)

9.
Depre C, Wang Q, Yan L et al (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 17, 1821-1828 crossref(new window)

10.
Bahrudin U, Morisaki H, Morisaki T et al (2008) Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol 384, 896-907 crossref(new window)

11.
Oliver MF (2014) Fatty acids and recovery during first hours of acute myocardial ischemia. Am J Cardiol 113, 285-286 crossref(new window)

12.
Ding Q, Dimayuga E, Markesbery WR and Keller JN (2006) Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J 8, 1055-1063 crossref(new window)

13.
Doll D, Sarikas A, Krajcik R and Zolk O (2007) Proteomic expression analysis of cardiomyocytes subjected to proteasome inhibition. Biochem Biophys Res Commun 2, 436-442 crossref(new window)

14.
Kisselev AF and Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8, 739-758 crossref(new window)

15.
Meiners S, Hocher B, Weller A et al (2004) Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 4, 471-477 crossref(new window)

16.
Meiners S, Dreger H, Fechner M et al (2008) Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension 2, 302-308 crossref(new window)

17.
Schlossarek S, Singh SR, Geertz B et al (2014) Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy. Front Physiol 5, 484 crossref(new window)

18.
Stansfield WE, Tang RH, Moss NC et al (2008) Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2, 645-650 crossref(new window)

19.
Kedi X, Ming Y, Yongping W et al (2009) Free cholesterol overloading induced smooth muscle cells death and activated both ER- and mitochondrial-dependent death pathway. Atherosclerosis 207, 123-130 crossref(new window)

20.
Rong JX, Shapiro M, Trogan E and Fisher EA (2003) Trans differentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A 100, 13531-13536 crossref(new window)

21.
Lee H, Yoo YS, Lee D and Song EJ (2013) Cholesterol induces cardiac hypertrophy by activating the AKT pathway. J Steroid Biochem Mol Biol 138, 307-313 crossref(new window)

22.
Liu B and Preisig PA (2002) Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int 62, 1650-1658 crossref(new window)

23.
Siddiqi S and Sussman MA (2014). The heart: mostly postmitotic or mostly premitotic? Myocyte cell cycle, senescence, and quiescence. Can J Cardiol 30, 1270-1278 crossref(new window)

24.
Dreger H, Westphal K, Weller A et al (2009) Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 83, 354-361 crossref(new window)

25.
Lüss H, Schmitz W and Neumann J (2002) A proteasome inhibitor confers cardioprotection. Cardiovasc Res 54, 140-151 crossref(new window)

26.
Li N, Wang HX, Han QY et al (2015) Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. J Mol Cell Cardiol 79, 303-314 crossref(new window)

27.
Weeks KL and McMullen JR (2011) The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology 26, 97-105 crossref(new window)

28.
Chen B, Ma Y, Meng R et al (2010) MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochim Biophys Sin 42, 253-258 crossref(new window)

29.
Hsieh V, Kim MJ, Gelissen IC et al (2014) Cellular cholesterol regulates ubiquitination and degradation of the cholesterol export proteins ABCA1 and ABCG1. J Biol Chem 289, 7524-7536 crossref(new window)

30.
Macías-Vidal J, Girós M, Guerrero M et al (2014) The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations. FEBS J 281, 4450-4466 crossref(new window)

31.
Meiners S, Ludwig A, Stangl V and Stangl K (2008) Proteasome inhibitors: poisons and remedies. Med Res Rev 28, 309-327 crossref(new window)

32.
Blagosklonny MV (2006) Cell senescence: hypertrophic arrest beyond the restriction point. J Cell Physiol 209, 592-597 crossref(new window)

33.
Busk PK, Bartkova J, Strøm CC et al (2002) Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res 1, 64-75 crossref(new window)

34.
Gavilán E, Giráldez S, Sánchez-Aguayo I et al (2015) Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3β dependent mechanism. Sci Rep 5, 10027 crossref(new window)

35.
Masamha CP and Benbrook DM (2009) Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69, 6565-6572 crossref(new window)

36.
Hu L, Su P, Li R et al (2015) Knockdown of microtubule actin crosslinking factor 1 inhibits cell proliferation in MC3T3-E1 osteoblastic cells. BMB Rep 48, 583-588 crossref(new window)